ClinicalTrials.gg

Program

Lamotrigine

Also written as “lamotrigine”, “Lamotrigine Tablets 25 mg” and “Lamictal”.

Its studies are mostly in Epilepsy · Bipolar Disorder · Epilepsy, Tonic-Clonic · Epilepsies, Partial · Schizophrenia, led by 9 companies.

Furthest: phase 4, since Aug 14, 200254 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline330 open or runningphase 4since Aug 14, 2002Aug 14, 2002none ahead
Dr. Reddy's Laboratories80 open or runningphase 1since May 26, 2010May 26, 2010none ahead
Teva Pharmaceutical Industries40 open or runningphase 1since Jan 30, 2009Jan 30, 2009none ahead
IPCA Laboratories20 open or runningphase 1since Jun 11, 2012Jun 11, 2012none ahead
Torrent Pharmaceuticals20 open or runningphase 1since Jul 13, 2009Jul 13, 2009none ahead
Viatris20 open or runningphase 1since Mar 30, 2008Mar 30, 2008none ahead
alembic-pharmaceuticals-ltd10 open or runningphase 1since Jan 9, 2018Jan 9, 2018none ahead
Desitin Arzneimittel10 open or runningphase 1since Dec 12, 2023Dec 12, 2023none ahead
Pharmtechnology10 open or runningphase 1since Mar 29, 2019Mar 29, 2019none ahead

Also a collaborator on its studies: biopharma-services-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 33 studies since Aug 14, 2002.

  1. May 26, 2010Dr. Reddy's Laboratories's first studies: 2 phase 1 studies in HealthyNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT01131975, NCT01131949
  2. May 12, 2011Phase 1 study in EpilepsyGlaxoSmithKline · NCT01357902 · 24 enrolled · Hong Kong
  3. Sep 1, 20112 phase 3 studies in EpilepsyGlaxoSmithKline · NCT01431976, NCT01431963
  4. Jan 17, 20122 phase 1 studies in HealthyDr. Reddy's Laboratories · NCT01513720, NCT01513681
  5. May 17, 2012Phase 3 study in Bipolar DisorderGlaxoSmithKline · NCT01602510 · 265 enrolled · China
  6. Jun 11, 2012IPCA Laboratories's first studies: 2 phase 1 studiesNew to IPCA LaboratoriesIPCA Laboratories · NCT01618825, NCT01618799
  7. Jun 13, 2013Phase 1 study in EpilepsyGlaxoSmithKline · NCT01879423 · 24 enrolled · China
  8. Jun 25, 20134 phase 1 studies in HealthyDr. Reddy's Laboratories · NCT01888263, NCT01888250, NCT01888757 and 1 more
  9. Feb 13, 2014Phase 1 study in EpilepsyGlaxoSmithKline · NCT02064465 · 138 enrolled · China
  10. Mar 27, 2014Phase 4 study in EpilepsyGlaxoSmithKline · NCT02100644 · 33 enrolled · Japan
  11. Jul 30, 2015Phase 1 study in Bipolar DisorderGlaxoSmithKline · NCT02513654 · 16 enrolled · China
  12. Jan 9, 2018alembic-pharmaceuticals-ltd's first study: phase 1 study in BioequivalenceNew to alembic-pharmaceuticals-ltdalembic-pharmaceuticals-ltd · NCT05145608 · 22 enrolled · Canada
  13. Mar 29, 2019Pharmtechnology's first study: phase 1 study in Healthy AdultsNew to PharmtechnologyPharmtechnology · NCT03898011 · 28 enrolled · Russian Federation
  14. Dec 12, 2023Desitin Arzneimittel's first study: phase 1 study in FastingNew to Desitin ArzneimittelDesitin Arzneimittel · NCT06199791 · 24 enrolled · Canada

TargetBeta

“Sodium channel alpha subunit blocker”ChEMBL 37, by rule

Other programs on the same 10 targets

ProgramCompanyFurthest phaseStudies
LidocaineruleKeenova Therapeuticsphase 463
Carbamazepinerulegrin-therapeutics-incphase 421
DronedaroneruleSanofiphase 418
chloroprocainerulesintetica-saphase 48
RiluzoleruleSanofiphase 46
PrilocaineruleHaisco Pharmaceutical Groupphase 42
CarticaineruleLaboratoires Theaphase 41
Ropivacainerulepainreform-ltdphase 317
PhenytoinruleViatrisphase 310
rufinamideruleEisaiphase 37

Studies

All 54 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06199791Fasting · Canada1CompletedDesitin ArzneimittelMay 9, 202324
NCT03898011Healthy Adults · Russian Federation1CompletedPharmtechnologyMay 4, 201928
NCT05145608Bioequivalence · Canada1Completedalembic-pharmaceuticals-ltdFeb 21, 201822
NCT02513654Bipolar Disorder · China1CompletedGlaxoSmithKlineNov 11, 201516
NCT02100644Epilepsy · Japan4CompletedGlaxoSmithKlineMay 11, 201533
NCT02064465Epilepsy · China1CompletedGlaxoSmithKlineJul 8, 2014138
NCT01888757Healthy · India1CompletedDr. Reddy's LaboratoriesSep 201062
NCT01888731Healthy · India1CompletedDr. Reddy's LaboratoriesAug 201062
NCT01888263Healthy · India1CompletedDr. Reddy's LaboratoriesAug 201032
NCT01888250Healthy · India1CompletedDr. Reddy's LaboratoriesAug 201036
NCT01879423Epilepsy · China1CompletedGlaxoSmithKlineJun 6, 201324
NCT01618825Lecithin Cholesterol Acyltransferase Deficiency · India1CompletedIPCA LaboratoriesMay 201228
NCT01618799Fasting State · India1CompletedIPCA LaboratoriesMay 201228
NCT01602510Bipolar Disorder · China3CompletedGlaxoSmithKlineDec 2015265
NCT01513720Healthy · United States1CompletedDr. Reddy's LaboratoriesDec 200220
NCT01513681Healthy · United States1CompletedDr. Reddy's LaboratoriesNov 200220
NCT01431976Epilepsy · Japan, Korea, Republic of3CompletedGlaxoSmithKlineFeb 201420
NCT01431963Epilepsy · Japan, Korea, Republic of3CompletedGlaxoSmithKlineMar 201370
NCT01357902Epilepsy · Hong Kong1CompletedGlaxoSmithKlineMay 23, 201124
NCT01131975Healthy · United States1CompletedDr. Reddy's LaboratoriesFeb 200326
NCT01131949Healthy · United States1CompletedDr. Reddy's LaboratoriesFeb 200326
NCT00939614Healthy · India1CompletedTorrent Pharmaceuticals
NCT00939458Healthy · India1CompletedTorrent Pharmaceuticals
NCT00838279Healthy · Canada1CompletedTeva Pharmaceutical IndustriesMar 200232
NCT00838136Healthy · Canada1CompletedTeva Pharmaceutical IndustriesMar 200232
NCT00835263Healthy · Canada1CompletedTeva Pharmaceutical IndustriesFeb 200232
NCT00834561Healthy · Canada1CompletedTeva Pharmaceutical IndustriesFeb 200232
NCT00723450Bipolar Disorder · United States3CompletedGlaxoSmithKlineAug 2013301
NCT00650208Healthy · United States1CompletedViatrisAug 200427
NCT00647751Healthy · United States1CompletedViatrisAug 200428
NCT00627575Epilepsy · United States1CompletedGlaxoSmithKlineSep 12, 2008119
NCT00605371Epilepsy · United States1CompletedGlaxoSmithKlineMar 6, 2008209
NCT00579982Mood Disorders · United States3CompletedGlaxoSmithKlineFeb 200897
NCT00566020Bipolar Disorder · Japan3CompletedGlaxoSmithKlineOct 201092
NCT00550407Bipolar Disorder · Japan3CompletedGlaxoSmithKlineOct 2009215
NCT00516139Epilepsy · United States3CompletedGlaxoSmithKlineJul 2010122
NCT00449774Mental Disorders · United States1CompletedGlaxoSmithKlineJun 19, 2007220
NCT00412191Epilepsy · Germany1CompletedGlaxoSmithKlineApr 27, 2007180
NCT00395694Epilepsy · Japan3CompletedGlaxoSmithKlineMar 1, 2009102
NCT00360126Bipolar Disorder · Australia4CompletedGlaxoSmithKlineFeb 200711
NCT00355082Epilepsies, Partial · United States, Argentina, Chile and more3CompletedGlaxoSmithKlineNov 2008226
NCT00264615Epilepsy · United States3CompletedGlaxoSmithKlineJun 200645
NCT00224510Bipolar Disorder · Netherlands, Spain3CompletedGlaxoSmithKlineSep 2006120
NCT00144872Seizures · United States1CompletedGlaxoSmithKlineApr 22, 200654
NCT00113165Epilepsy · United States, Argentina, Brazil and more3CompletedGlaxoSmithKlineJul 2007244
NCT00104416Epilepsy, Tonic-Clonic · United States, Argentina, Brazil and more3CompletedGlaxoSmithKlineJul 2008153
NCT00086593Schizophrenia · United States, Canada, United Kingdom3CompletedGlaxoSmithKlineJul 2005209
NCT00071747Schizophrenia · United States3CompletedGlaxoSmithKline176
NCT00067938Bipolar Disorder · United States4CompletedGlaxoSmithKlineAug 20041,200
NCT00056277Bipolar Disorder · United States3CompletedGlaxoSmithKlineAug 1, 2005150
NCT00044278Epilepsy · United States, Argentina, Australia and more2CompletedGlaxoSmithKlineJun 2006197
NCT00043914Epilepsy4CompletedGlaxoSmithKlineJan 29, 200372
NCT00043901Epilepsy, Tonic-Clonic · United States, Argentina, Chile and more4CompletedGlaxoSmithKlineNov 1, 2003141
NCT00043875Epilepsy · United States, Australia, Estonia and more2CompletedGlaxoSmithKlineNov 2003177

How it is read

Names in the registry

  • “Lamotrigine”, 26 entries
  • “lamotrigine”, 12 entries
  • “Lamotrigine Tablets 25 mg”, 4 entries
  • “Lamictal”, 3 entries
  • “Lamotrigine 25 mg Chewable Tablets”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.